Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

MARCH9 Inhibitors

MARCH9 inhibitors represent a specialized group of chemical compounds that specifically target the activity of Membrane-Associated RING-CH (MARCH) E3 ubiquitin ligase 9, a member of the MARCH family of proteins. These inhibitors function by interfering with the enzymatic activity of MARCH9, which plays a crucial role in the ubiquitination process. Ubiquitination is a post-translational modification where ubiquitin, a small regulatory protein, is attached to substrate proteins, often signaling them for degradation via the proteasome. MARCH9, in particular, is involved in regulating the stability and trafficking of various membrane proteins, including those associated with immune signaling and cellular homeostasis. Inhibition of MARCH9 can therefore significantly impact cellular processes by preventing the ubiquitination of target proteins, leading to alterations in protein degradation, cellular trafficking, and signaling pathways. The chemical structure of MARCH9 inhibitors is typically characterized by moieties that allow these molecules to interact specifically with the catalytic site of the MARCH9 enzyme. These inhibitors often contain functional groups that facilitate binding to the zinc-finger domain of the RING-CH motif, a critical site for ubiquitin ligase activity. Through this interaction, the inhibitors can effectively block the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to the substrate proteins. The precise design of these inhibitors often involves structural modifications to enhance selectivity and potency, ensuring that they specifically target MARCH9 without affecting other members of the MARCH family or unrelated ubiquitin ligases. The development and study of MARCH9 inhibitors are driven by a need to understand the fundamental mechanisms of protein regulation within the cell, with these inhibitors serving as valuable tools for dissecting the roles of MARCH9 in various biological processes, including those that govern protein stability, immune responses, and cellular signaling.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

Proteasome inhibitor, could block degradation of ubiquitinated proteins, indirectly affecting MARCH9 activity.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Alters endosomal pH, potentially affecting the ubiquitination processes mediated by MARCH9.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$65.00
$261.00
113
(3)

Autophagy inhibitor, could influence cellular processes related to MARCH9 function.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Inhibits vacuolar H+-ATPase, could affect endosomal processes influenced by MARCH9.

Leupeptin hemisulfate

103476-89-7sc-295358
sc-295358A
sc-295358D
sc-295358E
sc-295358B
sc-295358C
5 mg
25 mg
50 mg
100 mg
500 mg
10 mg
$73.00
$148.00
$316.00
$499.00
$1427.00
$101.00
19
(3)

Protease inhibitor, might affect protein degradation pathways involving MARCH9.

Eeyarestatin I

412960-54-4sc-358130B
sc-358130
sc-358130A
sc-358130C
sc-358130D
sc-358130E
5 mg
10 mg
25 mg
50 mg
100 mg
500 mg
$114.00
$203.00
$354.00
$697.00
$1363.00
$5836.00
12
(1)

ER-associated degradation inhibitor, might influence processes related to MARCH9 ubiquitination activity.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$188.00
$575.00
60
(2)

Proteasome inhibitor, could impact protein degradation processes involving MARCH9.

FCM Lysing solution (1x)

sc-3621
150 ml
$62.00
8
(1)

Alters endosomal pH, might affect MARCH9-mediated ubiquitination processes.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$155.00
$525.00
(1)

Ionophore that affects endosomal pH, potentially influencing MARCH9 activity.

Tunicamycin

11089-65-9sc-3506A
sc-3506
5 mg
10 mg
$172.00
$305.00
66
(3)

Inhibits N-linked glycosylation, possibly affecting proteins targeted by MARCH9.